Medidata Solutions said that Rave was selected by H Lundbeck initially in 2007 as an EDC system based on its ability to handle large and complex studies and its collaboration-enabling data collection, management and reporting capabilities.
Since then, H Lundbeck has used Medidata Rave in all Phase II–III clinical studies. The new multi-year contract allows for Rave use in all H Lundbeck’s upcoming Phases II and III trials.
Tarek Sherif, chairman and CEO of Medidata Solutions, said: “We have developed a strong partnership with H Lundbeck over the past two years and are proud to continue to support the company’s pipeline of CNS therapies.”
H Lundbeck is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, Alzheimer’s and Parkinson’s diseases.